Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Efficacy of semaglutide in IgA nephropathy with obesity: a case report.

Li H, Jia J, Wei L, Shang W, Liu Y

BMC nephrology2 Feb 2026Cited by 1 (Europe PMC)

PMID41629851 (opens in a new tab)PMCIDPMC12955259 (opens in a new tab)DOI10.1186/s12882-026-04784-6 (opens in a new tab)PepBankPUB-41629851
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 39-year-old man with IgA nephropathy and obesity, 24-hour proteinuria fell from 915 mg/day to 320 mg/day within four months of adding semaglutide.

    In plain wordsIn one man with IgA nephropathy and obesity, urine protein loss fell after semaglutide was added to his other treatment.

    Peptide
    Semaglutide
    Outcome
    Decrease24-hour proteinuria
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · four monthsAs given in this study (human).

    Measurements

    24-hour proteinuria
    915 mg/day
    before semaglutide
    24-hour proteinuria
    320 mg/day
    after semaglutide

    Source sentences

    Summary
    Following the introduction of semaglutide, a significant reduction in proteinuria was observed within four months, decreasing from 915 mg/day to 320 mg/day.
    1 context sentence
    Summary · context
    We then initiated treatment with semaglutide.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 39-year-old man with IgA nephropathy and obesity, body weight fell from 110 kg to 95 kg over four months of semaglutide.

    In plain wordsOne man with IgA nephropathy and obesity lost weight after semaglutide was added to his other treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · four monthsAs given in this study (human).

    Measurements

    Body weight
    110 kg
    before semaglutide
    Body weight
    95 kg
    after semaglutide

    Source sentences

    Summary
    Concurrently, the patient experienced a reduction in body weight, dropping from 110 kg to 95 kg over the same period.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 39-year-old man with IgA nephropathy and obesity, renal function remained stable throughout follow-up on semaglutide.

    In plain wordsIn one man with IgA nephropathy, kidney function stayed stable during follow-up on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeRenal function
    Study

    n = 1

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient's renal function remained stable throughout the follow-up
  4. 04HumanCase report or seriesSafety outcome

    In a 39-year-old man with IgA nephropathy and obesity, no significant adverse drug reactions were reported with semaglutide.

    In plain wordsOne man with IgA nephropathy and obesity reported no significant side effects from semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse drug reactions
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    no significant adverse drug reactions have been reported.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.